摘要
背景:阿尔茨海默病(AD)是一种以β淀粉样蛋白 (Aβ)蚀斑形成、tau蛋白病理、神经退行性病变和炎症过程为特征的神经退行性疾病。在阿尔茨海默病患者中,单核细胞参与炎症反应并被吸收至到病变大脑。最近的研究表明异常的表观遗传包括乙酰化与阿尔茨海默病的发形成有关。本研究的目的是检查两种转基因AD小鼠模型(三重转基因3xTg和一种过度表达瑞典荷兰爱荷华突变的淀粉样前体蛋白的模型)中的单核细胞中组蛋白H4乙酰化赖氨酸12(H4K12),从轻度认知功能障碍(MCI)和阿尔茨海默病患者中分离出的单核细胞比较。方法:小鼠和人类单核细胞通过以一种阳性的方法(pluriselect)(相对于阴性筛选法(miltenyi)来说)进行选择性分离。通过定量荧光试剂盒对组蛋白进行提取并对H4K12乙酰化进行分析。此外,通过7-AAD掺入流式细胞仪分析测定单核细胞因释放速率子的和对细胞死亡进行分析。结果:数据表明,脑内斑块沉积的发育过程中,转基因AD小鼠模型单核细胞H4K12乙酰化显著提高。并且,我们发现H4K12乙酰化升高发生在MCI病人而不是AD患者中。此外,我们观察到的AD小鼠和AD患者的单核细胞更容易受到细胞损伤(通过7-AAD掺入流式细胞仪分析观察),并表明促炎性细胞因子 (MIP2 and TNFα)的释放增强。结论:我们的研究结果表明外周血单核细胞的表观遗传改变是AD病的早期症状。因此,H4K12乙酰化可作为AD早期发展变化的一种新的生物标志物。
关键词: 乙酰化,阿尔茨海默病,表观遗传学,H4K12,组蛋白,MCI,单核细胞。
Current Alzheimer Research
Title:Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer’s Mice and in Human Patients
Volume: 12 Issue: 8
Author(s): Barbara Plagg, Daniela Ehrlich, Kathrin M Kniewallner, and Josef Marksteiner
Affiliation:
关键词: 乙酰化,阿尔茨海默病,表观遗传学,H4K12,组蛋白,MCI,单核细胞。
摘要: Background: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by amyloid-β (Aβ) plaque formation, tau pathology, neurodegeneration and inflammatory processes. Monocytes are involved in inflammation in AD and are recruited to the diseased brain. Recently it has been shown that aberrant epigenetic processes including acetylation are associated with the development of AD. The aim of the present study was to examine acetylation of histone H4 at lysine 12 (H4K12) in monocytes in two transgenic AD mouse models (the triple transgenic 3xTg and a model overexpressing amyloid-precursor protein APP with the Swedish-Dutch-Iowa mutations), and to compare with monocytes isolated from human patients with mild cognitive impairment (MCI) and AD. Methods: Mouse and human monocytes were selectively isolated with a positive (PluriSelect) respectively with a negative selection method (Miltenyi). Histones were extracted and acetylation of H4K12 was analyzed by a quantification fluorometric kit. Moreover, monocyte cytokine release was measured and cell death analyzed by FACS using incorporation of 7-AAD. Results: Our data show a significant increase of monocytic H4K12 acetylation in both transgenic AD mouse models early during development of the plaque deposition in the brain. In line with these data we found significantly elevated acetylation of H4K12 in human patients with MCI but not in patients with AD. Further we observed that the monocytes of AD mice and of AD patients were significantly more vulnerable to cell damage (as seen by 7-AAD incorporation in FACS analysis) and displayed an enhanced release of pro-inflammatory cytokines (MIP2 and TNFα). Conclusion: Our findings indicate that epigenetic changes in peripheral monocytes are an early event in AD-pathology. Thus H4K12 acetylation may be considered as a novel biomarker for early changes in AD development.
Export Options
About this article
Cite this article as:
Plagg Barbara, Ehrlich Daniela, Kniewallner, M Kathrin and Marksteiner Josef, Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer’s Mice and in Human Patients, Current Alzheimer Research 2015; 12 (8) . https://dx.doi.org/10.2174/1567205012666150710114256
DOI https://dx.doi.org/10.2174/1567205012666150710114256 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Study of Oxidized Lipids as Endogenous Substrates of P-gp (ABCB1)
Drug Metabolism Letters Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Human Endotoxemia as a Model of Systemic Inflammation
Current Medicinal Chemistry Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cerebral Hypoperfusion During Carotid Artery Stenosis can Lead to Cognitive Deficits that may be Independent of White Matter Lesion Load
Current Neurovascular Research Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Uric Acid in Metabolic and Cerebrovascular Disorders: A Review
Current Vascular Pharmacology Support and Social Contact as a Decisive Meta-Variable in Morbidity and Social Welfare of the Older Person
Current Aging Science Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry Chondromodulin-I and Tenomodulin: The Negative Control of Angiogenesis in Connective Tissue
Current Pharmaceutical Design DNA Damage and Repair in Alzheimers Disease
Current Alzheimer Research Modulation and Detection of Tau Aggregation with Small-Molecule Ligands
Current Alzheimer Research Animal Models for Testing Anti-Prion Drugs
Current Topics in Medicinal Chemistry Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology Advances in the Discovery of Novel Positive Allosteric Modulators of the α7 Nicotinic Acetylcholine Receptor
Recent Patents on CNS Drug Discovery (Discontinued) Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)